The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Dr. Vokes Discusses PARP Inhibitors in Lung Cancer

Everett E. Vokes, MD
Published Online:7:09 PM, Thu October 12, 2017

Everett E. Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medicine, and biological sciences chair, department of medicine, discusses PARP inhibitors for the treatment of lung cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.